August 27, 2026 3:09 PM
AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial
AstraZeneca said on Thursday its asthma drug Tezspire met the main goals of a late-stage trial in patients with a chronic inflammatory disorder of the oesophagus, offering a boost after a string of pipeline setbacks. The study showed that Tezspire, ...
